Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools.
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval for a wide range of applications in the United States and more than 40 countries around the World.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 31, 2023 | Post-IPO Equity | — | — | — | — | Detail |
Sep 24, 2021 | Post-IPO Equity | €12.50M | 2 | — | — | Detail |
Dec 16, 2019 | Post-IPO Equity | €7.50M | 1 | Johnson & Johnson Innovation – JJDC | — | Detail |
Feb 8, 2017 | Post-IPO Debt | €7M | 1 | IPF Partners | — | Detail |
Jul 15, 2011 | IPO | — | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
IPF Partners | Yes | Post-IPO Debt |
Psilos Group | Yes | Series B |
Armistice Capital | — | Post-IPO Equity |
Johnson & Johnson Innovation – JJDC | — | Post-IPO Equity |
Creadev | — | Series B |
Seventure Partners | — | Series B |